The biopharmaceutical company, founded in 2015 and based in Somerville, Massachusetts, has developed a lead program called XEN-101, which is an oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery. The company's therapeutics include a simple enteric-coated pill composed of components that deliver molecular oxygen to the lower gut, enabling doctors to treat obesity with gastric bypass microbiome. Xeno Biosciences aims to address the large unmet needs in obesity and related metabolic diseases with their innovative approach to biotechnology.